Vita Life Sciences Limited ASX Code: VSC Preliminary Year End - - PowerPoint PPT Presentation

▶
vita life sciences limited
SMART_READER_LITE
LIVE PREVIEW

Vita Life Sciences Limited ASX Code: VSC Preliminary Year End - - PowerPoint PPT Presentation

Dec 14, 2022 38 likes •181 views

Vita Life Sciences Limited ASX Code: VSC Preliminary Year End Results 31 December 2009 Brands Australia Y Y Malaysia Malaysia Y Y Y Y Singapore Y Thailand Y Y China Y Y Indonesia Y Vietnam Y 1 Sales Trend and Debt Levels

slide-1
SLIDE 1

Vita Life Sciences Limited

ASX Code: VSC

Preliminary Year End Results 31 December 2009

slide-2
SLIDE 2

Brands

Australia Y Y Malaysia Y Y Malaysia Y Y Singapore Y Thailand Y Y China Y Y Indonesia Y Vietnam Y

1

slide-3
SLIDE 3

Sales Trend and Debt Levels

30.1 15.5 11.1 11.8 17.0 $ ' Millions

  • Recovery has been achieved
  • Currently in profitable growth phase

2000 Listed on ASX 2003 Pan Recall & Delisted 2005 Eddie Tie appointed MD 2007 Relisted on ASX 2009 Health division profitable

Debt ($ ’m) 3.5 18.3 21.4 0.8 1.3

2

Events

slide-4
SLIDE 4

Product Reach

  • In Australia –products are sold in over 600 health food

stores;

  • In Malaysia – products are sold in 3 main channels
  • ver-the-counter (>800 stores), no-frills and multi-level
  • ver-the-counter (>800 stores), no-frills and multi-level

marketing (2,000 distributors);

  • In Singapore – VH products are sold in over 200 stores
  • In China, Thailand and Indonesia – less than 100

stores;

  • In Vietnam – sales commencing 3Q-2010;
  • In Thailand – MLM sales commencing 3Q-2010.

3

slide-5
SLIDE 5

Group’s Business Strategy

  • OTC – Australia, Malaysia, Singapore (Established

markets)

  • OTC – Thailand (2007), China (2008), Vietnam (2010),

Indonesia (2011)

  • MLM – Malaysia (2007), Singapore & Thailand (2010),

Indonesia (2011), Vietnam (2013)

  • Profit vs sensible market share
  • 50 million population markets

4

slide-6
SLIDE 6

Sales Revenue

  • Sales grew by 18.5%

in 2009 (2008: 21.3%)

11.1 11.1 11.8 14.4 17.0 8 10 12 14 16 18 $ million

  • Established business

grew by 17.3% (2008: 20.6%)

2 4 6 8 2005 2006 2007 2008 2009 A$ mi

5

slide-7
SLIDE 7

Sales Revenue - Segment

Others 1% Singapore 20%

2009

Australia Others 1% Singapore 22%

2008

  • Sales growth y-o-y for Australia, Malaysia and

Singapore were 26.5%, 10.9% and 3.3% respectively

Australia 49% Malaysia 30% 1%

6

Australia 46% Malaysia 31% 1%

slide-8
SLIDE 8

Normalised Profit

Income Statement ($ m) 2009 2008 EBIT (0.1) 0.5 Add / (less): Pan TGA Claim (costs) / receipts 0.6 (1.0)

7

Pan TGA Claim (costs) / receipts 0.6 (1.0) Normalised EBIT 0.5 (0.5) Interest expense (0.2) (0.2) Normalised net profit after tax 0.3 (0.8) Normalised EPS 0.6 cts (1.4) cts

slide-9
SLIDE 9

Normalised EBIT

(3.0) (1.8) (0.5) (0.6) 0.5

  • 2.00
  • 1.50
  • 1.00
  • 0.50
  • 0.50

A$ million

1. Excluding proceeds from Pan Liquidator of $0.70 million, $0.01 million and $1.04 million in 2005, 2007 and 2008 respectively 2. Excluding profit on disposal of Cyclopharm Limited of $11.8 million in 2006 3. Excluding income from settlement of legal case of $0.36 million and recovery of previously written off receivables of $0.16 million in 2007 4. Excluding Pan TGA Claim costs of $0.63 million in 2009 8

  • 3.00
  • 2.50

2005 2006 2007 2008 2009 Year

slide-10
SLIDE 10

Financial Summary – Balance Sheet

At 31 December ($ m) 2009 2008 Current assets 6.6 6.2 Non-current assets 2.2 2.4 Non-current assets 2.2 2.4 Total assets 8.8 8.6 Current liabilities (4.9) (4.8) Non-current liabilities (0.0) (0.0) Total liabilities (4.9) (4.8) Net assets 3.9 3.8

9

slide-11
SLIDE 11

Other

  • Group has an equity interest of 6.3% (20.1%

profit share) in a property project in Malaysia;

  • Project has a positive cash flow;
  • Project has a positive cash flow;
  • No funding required from Group.

10

slide-12
SLIDE 12

Health Division Outlook for 2010

  • 2009 sales trends forecast to continue
  • Continue to invest 30% – 40% of operating

profits in new businesses profits in new businesses

  • Improved profitability after investment in new

businesses

11

slide-13
SLIDE 13

Shareholder Information at 31 Jan. ‘10

Ordinary shares Ten largest quoted equity security holders Number held Percentage

  • f shares

issued Stinoc Pty Limited 8.04 14.8% Chemical Trustee Limited 7.56 13.9% Barleigh Wells Limited 7.37 13.6% Eddie L S Tie 3.35 6.2% Normandy Finance & Investments Asia Limited 2.15 2.9% Vital Bio Tech Holdings Limited 1.59 2.8% Normandy Nominees Limited 1.50 2.5%

12

Normandy Nominees Limited 1.50 2.5% OCI Construction Limited 1.37 2.5% Abasus Investments Limited 1.36 2.4% South Seas Holdings Pty Limited 1.28 2.3% 35.57 63.9% Total shares on issue 54,285,307 100.0% Category No of shareholders % 1 - 1,000 69 8.5% 1,001 - 5,000 340 41.8% 5,001 - 10,000 161 19.8% 10,001 - 100,000 208 25.6% 100,001 and over 36 4.4% Total shareholders 814 100.0%

slide-14
SLIDE 14

Thank You

13

24 February 2010